Epithalon vs Teriparatide
A side-by-side research comparison of Epithalon and Teriparatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Epithalon | Teriparatide |
|---|---|---|
| Full name | Epithalon (Epitalon / Epithalone) | Teriparatide (PTH 1-34) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | FDA-approved drug (prescription) |
| Mechanism | Activates telomerase reverse transcriptase (hTERT) expression for telomere maintenance. Also normalizes circadian rhythm via melatonin regulation and modulates antioxidant enzymes. | Intermittent dosing of PTH 1-34 preferentially stimulates osteoblasts (bone-building cells) over osteoclasts, increasing bone formation, trabecular bone mass, and bone strength. |
| Molecular weight | 390.4 Da | 4117.8 Da |
| Half-life | 3-4 hours | ~1 hour (subcutaneous) |
| Bioavailability | High (SubQ) | ~95% subcutaneous |
| Typical dose | 5-10 mg | 20 mcg once daily (medical) |
| Frequency | Daily for 10-20 days | Once daily |
| Route | Subcutaneous injection | Subcutaneous injection |
Epithalon reported benefits
- Telomerase activation
- Telomere lengthening
- Melatonin normalization
- Improved sleep patterns
- Antioxidant enzyme upregulation
- Potential lifespan extension
Teriparatide reported benefits
- Actively builds new bone
- Increases bone mineral density
- Reduces fracture risk (medical)
- Supports bone healing
Related comparisons
Research and educational reference only. Not medical advice.